Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

26.85
-1.0200-3.66%
Post-market: 27.160.3100+1.15%16:49 EDT
Volume:1.15M
Turnover:31.08M
Market Cap:3.21B
PE:-12.52
High:27.97
Open:27.80
Low:26.67
Close:27.87
52wk High:42.21
52wk Low:23.05
Shares:119.54M
Float Shares:92.51M
Volume Ratio:1.41
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:5.08
PE(LYR):-15.60

Loading ...

Company Profile

Company Name:
NEWAMSTERDAM PHARMA CO NV
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
100
Office Location:
Gooimeer 2-35,Naarden,Noord-Holland,Netherlands
Zip Code:
1411 DC
Fax:
- -
Introduction:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Directors

Name
Position
Michael Davidson
Chief Executive Officer and Executive Director
Adele Gulfo
Non-Executive Director
James N. Topper
Non-Executive Director
Janneke van der Kamp
Non-Executive Director
John Kastelein
Chief Scientific Officer and Non-Executive Director
John W. Smither
Non-Executive Director
Louis Lange
Non-Executive Director
Mark C. McKenna
Non-Executive Director and Vice Chair
William H. Lewis
Chair and Non-Executive Director
Wouter Joustra
Non-Executive Director

Shareholders

Name
Position
Michael Davidson
Chief Executive Officer and Executive Director
Ian Somaiya
Chief Financial Officer
John Kastelein
Chief Scientific Officer and Non-Executive Director
Louise Kooij
Chief Accounting Officer